Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Assets Average (2020 - 2025)

Historic Assets Average for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $215.6 million.

  • Foghorn Therapeutics' Assets Average fell 3230.34% to $215.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.6 million, marking a year-over-year decrease of 3230.34%. This contributed to the annual value of $284.9 million for FY2024, which is 1750.16% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Assets Average stood at $215.6 million, which was down 3230.34% from $242.5 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Assets Average high stood at $504.0 million for Q1 2022, and its period low was $197.3 million during Q3 2021.
  • In the last 5 years, Foghorn Therapeutics' Assets Average had a median value of $299.7 million in 2023 and averaged $322.7 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Assets Average surged by 12575.86% in 2022 and then crashed by 3230.34% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Assets Average stood at $352.9 million in 2021, then grew by 18.84% to $419.4 million in 2022, then dropped by 28.55% to $299.7 million in 2023, then dropped by 1.17% to $296.2 million in 2024, then dropped by 27.21% to $215.6 million in 2025.
  • Its Assets Average stands at $215.6 million for Q3 2025, versus $242.5 million for Q2 2025 and $271.3 million for Q1 2025.